Role of nitric oxide in the development of tolerance to diazepam-induced motor impairment in mice

Pharmacological Reports

Volumn 60, Issue 4, 2008, Pages 475-482

  Talarek, Sylwia ^a   Listos, Joanna ^a   Fidecka, Sylwia ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Diazepam; Mice; Motor impairment; Nitric oxide; Tolerance

Indexed keywords

7 NITROINDAZOLE; DIAZEPAM; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMNEY TEST; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERANCE; EXPERIMENTAL MOUSE; LONG TERM CARE; MENTAL TEST; MONOTHERAPY; MOTOR ACTIVITY; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROTRANSMISSION; NONHUMAN; OUTCOME ASSESSMENT; RAT; REPEATED DRUG DOSE; ROTAROD TEST; SINGLE DRUG DOSE; TASK PERFORMANCE; TREATMENT DURATION;

EID: 52049122625     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. A receptor operated chloride channels. J Pharm Pharmacol, 1992, 261, 395-402.
2. Allison C, Pratt JA: Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence. Pharmacol Ther, 2003, 98, 171-195.
3. Babbedge RC, Bland-Ward PA, Hart SL, Moore PK: Inhibition of rat cerebellar nitric oxide synthase by 7-nitroindazole and related substituted indazoles. Br J Pharmacol, 1993, 110, 225-228.
4. Babey AM, Kolesnikov Y, Cheng J, Inturrisi CE, Trifilletti RR, Pasternak GW: Nitric oxide and opioid tolerance. Neuropharmacology, 1994, 33, 1463-1470.
5. A receptor modulators. Eur Neuropsychopharmacology, 2003, 13, 411-423.
6. Boisser JR, Tardy J, Diverres JC: A new simple method for exploration of "tranquilizers" action: the chimney test. Med Exp, 1960, 3, 81-84.
7. Dietl W, Bauer M, Podesser BK: Nitric oxide in cardiac transplantation. Pharmacol Rep, 2006, 58, 142-152.
8. Dunham NW, Miya TS: A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Am Pharm Assoc (Baltim), 1957, 46, 208-209.
9. Dunn RW, Reed TAW, Copeland PD, Frye ChA: The nitric oxide synthase inhibitor 7-nitroindazole displays enhanced anxiolytic efficacy without tolerance in rats following subchronic administration. Neuropharmacology, 1998, 37, 899-904.
10. File SE: Tolerance to the behavioral actions of benzodiazepines. Neurosci Biobehav Rev, 1985, 9, 113-121.
11. File SE, Fernandes C: Dizocilpine prevents the development of tolerance to the sedative effects of diazepam in rats. Pharmacol Biochem Behav, 1994, 47, 823-826.
12. A receptor. Neuroreport, 1998, 9, 1089-1093.
13. Gallager DW, Lakoski JM, Gonsalves SF, Rauch, SL: Chronic benzodiazepine treatment decreases postsynaptic GABA sensitivity. Nature, 1984, 308, 74-77.
14. Gallager DW, Malcom AB, Andersen SA, Gonsales SF: Continuous release of diazepam: electrophysiological, biochemical and behavioral consequences. Brain Res, 1985, 342, 26-36.
15. Garthwaite J, Boulton CL: Nitric oxide signaling in the central nervous system. Annu Rev Physiol, 1995, 57, 683-706.
16. Greenblatt DJ, Shader RI: Dependence, tolerance and addiction to benzodiazepines: clinical and pharmacokinetic considerations. Drug Metab Rev, 1978, 8, 13-28.
17. Greenblatt DJ, Shader RI: Long-term administration of benzodiazepines: pharmacokinetic versus pharmacodynamic tolerance. Psychopharmacol Bull, 1986, 22, 416-423.
18. Guevara-Guzinan R, Emson CP, Kendrick KM: Modulation of in vivo striatal transmitter release by nitric oxide and cyclic GMP. J Neurochem, 1994, 62, 807-810.
19. Guix FX, Uribesalgo I, Coma M, Munoz FJ: The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol, 2005, 76, 126-152.
20. Itzhak Y: Modulation of cocaine- and methamphetamine-induced behavioral sensitization by inhibition of brain nitric oxide synthase. J Pharmacol Exp Ther, 1997, 282, 521-527.
21. Khanna JM, Morato GS, Chau A, Shah G: Influence of nitric oxide synthase inhibition on the development of rapid tolerance to ethanol. Brain Res Bull, 1995, 37, 599-604.
22. Khanna JM, Morato GS, Shah G, Chau A, Kalant H: Inhibition of nitric oxide synthesis impairs rapid tolerance to ethanol. Brain Res Bull, 1993, 32, 43-47.
23. Kippin TE, Pinel JJP, Kornecook TJ, Kalynchuk LE: Noncontingent drug exposure facilitates the development of contingent tolerance to the anticonvulsant effects of ethanol and diazepam in kindled rats. Pharmacol Biochem Behav, 1998, 61, 143-148.
24. Kraus MM, Prast H: Involvement of nitric oxide, cyclic GMP and phosphodiesterase 5 in excitatory amino acid and GABA release in the nucleus accumbens evoked by activation of the hippocampal fimbria. Neuroscience, 2002, 112, 331-343.
25. A receptor function. J Pharmacol Exp Ther, 1988, 246, 170-177.
26. Lonart G, Wang J, Johnson KM: Nitric oxide induces neurotransmitter release from hippocampal slices. Eur J Pharmacol, 1992, 220, 271-272.
27. Lue WM., Su MT, Lin WB, Tao PT: The role of nitric oxide in the development of morphine tolerance in rat hippocampal slices. Eur J Pharmacol, 1999, 383, 129-135.
28. Majeed NH, Przewłocka B, Machelska H, Przewłocki R: Inhibition of nitric oxide synthase attenuates the development of morphine tolerance and dependence in mice. Neuropharmacology, 1994, 33, 189-192.
29. Michel T, Feron O: Nitric oxide synthases: which, where, how, and why? J Clin Invest 1997, 100, 2146-2152.
30. Monti JM, Hantos H, Ponzoni A, Monti D, Banchero P: Role of nitric oxide in sleep regulation: effects of L-NAME, an inhibitor of nitric oxide synthase, on sleep in rats. Behav Brain Res, 1999, 100, 197-205.
31. Nidhi G, Bhargava VK, Pandhi P: Tolerance to and withdrawal from anticonvulsant action of diazepam: role of nitric oxide. Epilepsy Behav, 2000, 1, 262-270.
32. O'Dell TJ, Hawkins RD, Kandel ER, Arancio O: Test of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. Proc Natl Acad Sci USA, 1991, 88, 11285-11289.
33. Quock RM, Nguyen E: Possible involvement of nitric oxide in chlordiazepoxide-induced anxiolysis in mice. Life Sci, 1992, 51, 255-260.
34. Rees DD, Palmer RMJ, Schultz R, Hodson HF, Moncada S: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol, 1990, 101, 746-752.
35. Roca DJ, Rosenberg I, Farrant M, Farb DH: Chronic agonist exposure induces downregulation and allosteric uncoupling of the GABA/ benzodiazepine receptor complex. Mol Pharmacol, 1990, 37, 37-43.
36. Rosenbaum JF: Benzodiazepines: revisiting clinical issues in treating anxiety disorders. J Clin Psychiatry, 2005, 7, 23-32.
37. Rosenberg HC, Tietz EI, Chui TH: Tolerance to the anticonvulsant action of benzodiazepines: relationship to decreased receptor density. Neuropharmacology, 1995, 24, 639-644.
38. Segovia G, Porras A, Mora F: Effects of a nitric oxide donor on glutamate and GABA release in striatum and hippocampus of the conscious rat. Neuroreport, 1994, 5, 1937-1940.
39. Shim I, Kim KT, Kim YH, Chun BG, Hahm DH, Lee Eunjoo H, Kim SE, Lee HJ: Role of nitric oxide synthase inhibitors and NMDA receptor antagonist in nicotine-induced behavioral sensitization in the rat. Eur J Pharmacol, 2002, 443, 119-124.
40. Smith RL, Barrett RJ: Tolerance to the anticonflict effects of diazepam: importance of methodological considerations. Pharmacol Biochem Behav, 1997, 58, 61-66.
41. Stephen DN: A glutamatergic hypothesis of drug dependence: extrapolation from BDZ ligands. Behav Pharmacol, 1999, 6, 425-446.
42. Talarek S, Fidecka S: Involvement of nitricoxidergic system in the hypnotic effects of benzodiazepines in mice. Pol J Pharmacol, 2004, 56, 719-726.
43. Talarek S, Fidecka S: Role of nitric oxide in anticonvulsant effects of benzodiazepines in mice. Pol J Pharmacol, 2003, 55, 181-191.
44. Talarek S, Fidecka S: Role of nitric oxide in benzodiazepines-induced antinociception in mice. Pol J Pharmacol, 2002, 54, 27-34.
45. Tallman JF, Gallager DW: The GABAergic system: a locus of benzodiazepine action. Annu Rev Neurosci, 1985, 8, 21-44.
46. Tietz EI, Chui TH, Rosenberg HC: Regional GABA/BDZ receptors/chloride channel coupling after acute and chronic BDZ treatment. Eur J Pharmacol, 1989, 167, 57-69.
47. Trabace L, Kendrick KM: Nitric oxide can differentially modulate striatal neurotransmitter concentrations via soluble guanylate cyclase and peroxynitrite formation. J Neurochem, 2000, 75, 1664-1674.
48. Tutka P, Barczyński B, Arent K, Mosiewicz J, Mróz T, Wielosz M: Different effects of nitric oxide synthase inhibitors on convulsions induced by nicotine in mice. Pharmacol Rep, 2007, 59, 259-267.
49. Tyma JL, Rosenberg HC, Chui TH: Radioreceptor assay of benzodiazepines in cerebrospinal fluid during chronic flurazepam treatment in cats. Eur J Pharmacol, 1984, 105, 301-308.
50. Ulusu UI, Uzbay T, Kayir H, Alici T, Karakas S: Evidence for the role of nitric oxide in nicotine-induced locomotor sensitization in mice. Psychopharmacology, 2005, 178, 500-504.
51. Uzbay IT, Coskun I, Kayir H, Ozturk N, Ozturk Y: Extract of Hypericum perforatum blocks caffeine-induced locomotor activity in mice: a possible role of nitric oxide. Phytother Res, 2007, 21, 415-419.
52. Uzbay IT, Oglesby MW: Nitric oxide and substance dependence. Neurosci Biobehav Rev, 2001, 25, 43-52.
53. Valtschanoff JG, Weinberg RJ, Rustioni A, Schmidt HH: Nitric oxide synthase and GABA colocalize in lamina II of rat spinal cord. Neurosci Lett, 1992, 148, 6-10.
54. Vaupel DB, Kimes AS, London ED: Further in vivo studies on attenuating morphine withdrawal: isoform-selective nitric oxide synthase inhibitors differ in efficacy. Eur J Pharmacol, 1997, 324, 11-20.
55. Wazlawik E, Morato GS: Effects of intracerebroventricular administration of 7-nitroindazole on tolerance to ethanol. Brain Res Bull, 2002, 57, 165-170.
56. Woods JH., Katz JL, Winger G: Benzodiazepines: use, abuse and consequences. Pharmacol Rev, 1992, 44, 151-338.
57. Yamada K, Noda Y, Nakayama Y, Komori H, Sugihara T, Hasegawa T, Nabeshima T: Role of nitric oxide in learning and memory and in monoamine metabolism in the rat brain. Br J Pharmacol, 1995, 115, 852-858.
58. Yan XX, Jen LS, Garey LJ: NADPH-diaphorase-positive neurons in primate cerebral cortex colocalize with GABA and calcium-binding proteins. Cereb Cortex, 1996, 6, 524-529.
59. A receptors. Neurosci Lett, 1994, 180, 239-242.